Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLORENCE: Febuxostat vs Allopurinol for TLS Prevention
NCT01724528Phase 3Completed
- Sponsor
- Menarini Group
- Start
- Oct 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of febuxostat in tumor lysis syndrome (TLS), sponsored by Menarini Group. Started Oct 2012; status: completed.
02
Drugs
febuxostat
03
Conditions
tumor lysis syndrome (TLS)
Beyond the preview
Go deeper on NCT01724528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01724528.